Showing 6481-6490 of 7128 results for "".
- Brickell Secures Rights to a Novel Class of RORγ Inhibitors for Psoriasis and Other Autoimmune Diseaseshttps://practicaldermatology.com/news/brickell-biotech-secures-rights-to-a-novel-class-of-ror-inhibitors-for-psoriasis-and-other-autoimmune-diseases/2458801/Brickell Biotech, Inc. has secured the exclusive world-wide rights to a series of novel retinoic acid–related orphan nuclear receptor gamma (RORy) inhibitors from Orca Pharmaceuticals (Orca) and New York University (NYU). This chemical series is based on intellectual property emerg
- Pfizer and Allergan to Combinehttps://practicaldermatology.com/news/pfizer-and-allergan-to-combine/2458803/The boards of directors for Pfizer Inc. and Allergan plc have both unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer will combine with Allergan in a stock transaction currently valued at $363.63 per Allergan share, for a total enterprise v
- Almirall Acquires Veltin® and Altabax® from Stiefel, a GSK Companyhttps://practicaldermatology.com/news/almirall-acquires-veltin-and-altabax-from-stiefel-a-gsk-company/2458802/Almirall has acquired the rights to Veltin® and Altabax, from Stiefel, a GSK company, in exchange for distribution rights to Toctino® and an undisclosed cash payment.
- Ortek Therapeutics Files Patent Applications for New Microbiome to Reduce S. Aureus Proliferationhttps://practicaldermatology.com/news/ortek-therapeutics-files-patent-applications-for-new-microbiome-to-reduce-s-aureus-proliferation/2458808/Stony Brook University and Ortek Therapeutics, Inc. filed two patent applications in the United States and internationally for nutrient based compositions utilizing innovative microbiome technology. Developed at Stony Brook University, these compositions have been exclusively licensed to Ortek as
- Dr. Jennifer Nam Choi Appointed Chief of OncoDermatology for Northwestern Medicinehttps://practicaldermatology.com/news/dr-jennifer-nam-choi-appointed-chief-of-oncodermatology-for-northwestern-medicine/2458809/Jennifer Nam Choi, MD, has been named Chief of the Division of OncoDermatology at Northwestern Memorial Hospital and associate professor in the Department of Dermatology at Northwestern University Feinberg School of Medicine. Dr. Choi is an accomplished dermatologist specializing in the mana
- Data Show Acne Patients Don't Understand Risks Associated with Antibiotic Treatmenthttps://practicaldermatology.com/news/data-show-acne-patients-dont-understand-risks-associated-with-antibiotic-treatment/2458805/Widespread and inappropriate use of antibiotics continues to be a problems in the US leading to antibiotic resistance issues. While most people understand how the overuse of antibiotics to treat viral infections contributes to this issue, according to Galderma, new data reveal that acne patients
- ASDS Awards 10 Clinical Research Grantshttps://practicaldermatology.com/news/asds-awards-10-clinical-research-grants/2458811/The American Society for Dermatologic Surgery (ASDS) has awarded a total of $96,000 to 10 new clinical research projects through its Cutting Edge Research Grant program. This year’s research projects will focus on topics ranging from examining the effectiveness of specific lasers on surgica
- Cosmetic Bootcamp University Exceeds Goalshttps://practicaldermatology.com/news/cosmetic-bootcamp-university-a-success/2458815/Now completing its session in Philadelphia, the Cosmetic Bootcamp University session has exceeded goals, organizers report. Cosmetic Bootcamp seeks to improve patient outcomes in a manner not possible at other meetings by focusing on core specialists in dermatology, plastic surgery, op
- Immune Pharmaceuticals: FDA Accepts IND Application for Bertilimumab for Bullous Pemphigoidhttps://practicaldermatology.com/news/immune-pharmaceuticals-fda-accepts-ind-application-for-bertilimumab-for-bullous-pemphigoid/2458813/Immune Pharmaceuticals, Inc. has indicated that the FDA has accepted the Company's Investigational New Drug (IND) application for its first in class, lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP). This FDA acceptance enables the Company to expand recruitme
- LEO Pharma to Acquire Global Dermatology Portfolio from Astellashttps://practicaldermatology.com/news/leo-pharma-to-acquire-global-dermatology-portfolio-from-astellas/2458818/LEO Pharma A/S and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million. Under the terms of the agreement, the assets and associated respon